Search | Clinical Trials Finder

Conditions: Hepatitis C
Interventions: Telaprevir, Peginterferon alfa-2b, Ribavirin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 13
States / cities: Phoenix, Arizona • San Francisco, California • Denver, Colorado + 10 more

Conditions: HCV Infection
Interventions: placebo, ANA598, Peginterferon, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 20
States / cities: Anaheim, California • Los Angeles, California • San Clemente, California + 17 more

Conditions: Hepatitis, Chronic Active
Interventions: CPG10101, Control; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 14
States / cities: Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more

Conditions: Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions: ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more

Conditions: Hepatitis C, Hiv, Coinfection, HIV, Substance Use Disorders
Interventions: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hepatitis C
Interventions: telaprevir, ribavirin, peginterferon alfa-2a; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 57 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: La Jolla, California • Long Beach, California • Sacramento, California + 13 more

Conditions: Hepatitis C, Human Immunodeficiency Virus
Interventions: SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lutherville, Maryland

Conditions: Hepatitis C, Chronic
Interventions: Ribavirin, Peginterferon alfa-2a; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 58
States / cities: Scottsdale, Arizona • Tucson, Arizona • Anaheim, California + 46 more

Conditions: Chronic Hepatitis C Infection
Interventions: GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more

Conditions: Treatment of Hepatitis C
Interventions: Ledipasvir/Sofosbuvir FDC; Drug
Lead sponsor: Peter J. Ruane, M.D., Inc.; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatitis C, Chronic
Interventions: BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV), Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 18
States / cities: North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more

Conditions: Hepatitis C
Interventions: 200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C
Interventions: BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 6
States / cities: Tulepo, Mississippi • New York, New York • Germantown, Tennessee + 3 more

Conditions: HCV Infection
Interventions: ABT-267, Placebo, Blood Sample Collection, Cytochrome P450 inhibitor; Drug · Procedure
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Orlando, Florida • Waukegan, Illinois • San Antonio, Texas

Conditions: Hepatitis C
Interventions: Peginterferon alfa-2a, Ribavirin, telaprevir; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Atlanta, Georgia • Burlington, Vermont

Conditions: Hepatitis C
Interventions: Sofosbuvir, Placebo, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more

Conditions: Hepatitis C, HIV
Interventions: GS-7977/GS- 5885 FDC; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hepatitis C
Interventions: SCV-07; Drug
Lead sponsor: SciClone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Anaheim, California • Louisville, Kentucky • Cincinnati, Ohio + 1 more

Conditions: Chronic Hepatitis C Infection
Interventions: ABT-267, ABT-450, ABT-333, Ritonavir, Ribavirin; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Bakersfield, California • Orlando, Florida • Annapolis, Maryland + 1 more

Conditions: Hepatitis C, Chronic, HIV CDC Category A1
Interventions: Sofosbuvir + Simeprevir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatitis C
Interventions: Peg-Intron, REBETOL, HCV 796; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 34
States / cities: Anaheim, California • La Jolla, California • Los Angeles, California + 26 more

Conditions: Chronic Hepatitis C
Interventions: Daclatasvir, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Anaheim, California • Orlando, Florida • Baltimore, Maryland + 4 more

Search by objective public record fields.

An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Zepatier in Patients with Substance Use

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)

Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV

Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C

A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects